Intercellular Adhesion Molecule 1 – New Report by Stages of Development, Therapy Area, and Companies & Pipeline Review, H1 2018
Intercellular Adhesion Molecule 1
Overview
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Intercellular Adhesion Molecule 1 (ICAM-1) is a protein encoded by the ICAM1 gene. It acts as a receptor for major receptor group rhinovirus A-B capsid proteins and Coxsackievirus A21 capsid proteins. ICAM1 promotes the assembly of endothelial apical cups through ARHGEF26/SGEF and RHOG activation.
Click here for sample report @ https://www.wiseguyreports.com/sample-request/2811480-intercellular-adhesion-molecule-1-major-group-rhinovirus-receptor-or-cd54
Major Key Players:
Atlantic Healthcare Plc
China Medical System Holdings Ltd
RXi Pharmaceuticals Corp
Intercellular Adhesion Molecule 1 Industry Major Outlook
Pharmaceutical and Healthcare latest pipeline guide Intercellular Adhesion Molecule 1 - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Intercellular Adhesion Molecule 1 , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 1, 1 and 1 respectively.
Intercellular Adhesion Molecule 1 pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Intercellular Adhesion Molecule 1 - Competitive Analysis
Key players are making innovative developments in Intercellular Adhesion Molecule 1 industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector
Scope
The pipeline guide provides a snapshot of the global therapeutic landscape of Intercellular Adhesion Molecule 1.
The pipeline guide reviews pipeline therapeutics for Intercellular Adhesion Molecule 1 by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Intercellular Adhesion Molecule 1 therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Intercellular Adhesion Molecule 1 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Intercellular Adhesion Molecule 1.
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2811480-intercellular-adhesion-molecule-1-major-group-rhinovirus-receptor-or-cd54
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Posted by
Vivian Dsena
on Monday February 26 2018, 2:02 AM EST.
All trademarks acknowledged.
Filed under Uncategorized.
Comments and Trackbacks closed.
Follow responses:
RSS 2.0
